Article

Sugar Crash on the PI3K Pathway: The First Documented Case of Inavolisib-Associated Diabetic Ketoacidosis

2026-07-07

Abstract excerpt

<h4>Background: </h4> and Clinical Significance: Phosphatidylinositol-3-kinase (PI3K) inhibitors have transformed the treatment of advanced hormone receptor-positive, HER2-negative breast cancer harboring PIK3CA mutations. Hyperglycemia is a well-recognized on-target adverse effect of this drug class; however, progression to diabetic ketoacidosis (DKA) is rare and potentially life-threatening. Inavolisib, a next-g...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 1beb6744-74ce-5d25-a861-c0e25c86a6f7
DOI: 10.20944/preprints202606.1708.v2

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Sugar Crash on the PI3K Pathway: The First Documented Case of Inavolisib-Associated Diabetic KetoacidosisDOI 10.20944/preprints202606.1708.v2Read

Sugar Crash on the PI3K Pathway: The First Report of Inavolisib-Associated Diabetic KetoacidosisSemantic proximity Read

Paradoxical Diabetic Ketoacidosis in a Type 2 Diabetes patient on Dapagliflozin: A Brief Case ReportSemantic proximity Read

CRISIS HIPERGLICÉMICA AGUDA COMO DEBUT DE DIABETES MELLITUS Y COVID-19: ¿UNA NUEVA CAUSA DE DIABETES?Semantic proximity Read

Predisposing factors for the development of diabetic ketoacidosis with lower than anticipated glucose levels in type 2 diabetes patients on SGLT2-inhibitors: a review.Semantic proximity Read

A risk analysis of alpelisib-induced hyperglycemia in patients with advanced solid tumors and breast cancerSemantic proximity Read

Inavolisib for HR-Positive, HER2-Negative Advanced Breast Cancer: Clinical Trials and Patient Access Implication.Semantic proximity Read

Safety analyses of the INAVO120 randomised phase III trial of inavolisib or placebo with palbociclib-fulvestrant in patients with PIK3CA-mutated, hormone receptor-positive, HER2-negative, endocrine-resistant advanced breast cancer.Semantic proximity Read

Phase I/Ib Trial of Inavolisib Plus Palbociclib and Endocrine Therapy for PIK3CA-Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced or Metastatic Breast Cancer.Semantic proximity Read

Distinct glycaemic safety reporting patterns for alpelisib and capivasertib: a disproportionality analysis of the FAERS databaseSemantic proximity Read

Itaconate delays type 2 diabetes progression by alkylating RIPK3 to inhibit pancreatic β‑cell failureSemantic proximity Read

Inavolisib: a second-generation PI3Kα inhibitor in HR+/HER2-negative breast cancer.Semantic proximity Read

Rational Design of Potent and Orally Efficacious PI3Kα/δ Degrader for PIK3CA Mutant Breast Cancer without Hyperglycemic Liability.Semantic proximity Read